http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#Head http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#assertion http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#provenance http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#pubinfo http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#assertion http://purl.obolibrary.org/obo/DOID_12799 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_12799 http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01271 http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#association http://www.w3.org/2000/01/rdf-schema#label elaprase is indicated for patients with hunter syndrome mucopolysaccharidosis ii mps ii elaprase has been shown to improve walking capacity in patients 5 years and older in patients 16 months to 5 years of age no data are available to demonstrate improvement in disease related symptoms or long term clinical outcome however treatment with elaprase has reduced spleen volume similarly to that of adults and children 5 years of age and older the safety and efficacy of elaprase have not been established in pediatric patients less than 16 months of age see use in specific populations 8 4 elaprase is a hydrolytic lysosomal glycosaminoglycan gag specific enzyme indicated for patients with hunter syndrome mucopolysaccharidosis ii mps ii elaprase has been shown to improve walking capacity in patients 5 years and older in patients 16 months to 5 years of age no data are available to demonstrate improvement in disease related symptoms or long term clinical outcome however treatment with elaprase has reduced spleen volume similarly to that of adults and children 5 years of age and older the safety and efficacy of elaprase have not been established in pediatric patients less than 16 months of age 1 http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB01271 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#provenance http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#pubinfo http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#sig http://purl.org/nanopub/x/hasSignature Q9KMiKzTI2rrweLNd9j3dd6C0eayGqo7dJkMjRz6I/ITe0Cl6k5u6zMKUoeqM0unGqXpP0mdVYjF0rPpOUyDmkcdUSOxgBz86/M9dCCwd5LCD5/VTZxR+5uw/IJi2nhUEUkD0XzxdPsoE5kx2oBdu85P22AOIUKTMNhUHoIfBis= http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs http://purl.org/dc/terms/created 2021-06-12T13:30:39.307+02:00 http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAYyW5a_et_ds_hN43B9vpKSctDrk0jg5NvOsuAfL15bs https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs